Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon α2a or α2b

Antiviral Therapy

Volumn 13, Issue 4, 2008, Pages 511-517

  Vispo, Eugenia ^a   Barreiro, Pablo ^a   Rodríguez Nóvoa, Sonia ^a   Morello, Judit ^a   Labarga, Pablo ^a   Martín Carbonero, Luz ^a   Maida, Ivana ^a   García Gascó, Pilar ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIXED INFECTION; PRESCRIPTION; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; KINETICS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 47649127526     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Rockstroh J, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192:992-1002.
2. Weber R, Sabin C, Friis-Moller N, et al. Liver-related deaths in persons infected with the HIV: the D:A:D study. Arch Intern Med 2006; 166:1632-1641.
3. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292:2839-2848.
4. Chung R, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 35:451-459.
5. Torriani F, Rodriguez-Torres M, Rockstroh J, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450.
6. Nuñez M, Miralles C, Berdún MA, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO Trial. AIDS Res Hum Retroviruses 2007; 23:972-982.
7. Fried M, Shiffman M, Reddy K, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
8. Manns M, McHutchison J, Gordon S, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
9. Grace M, Lee S, Bradshaw S, et al. Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signalling pathway. J Biol Chem 2005; 280:6327-6336.
10. Bailon P, Palleroni A, Schaffer C, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001; 12:195-202.
11. Glue P, Fang J, Rouzier-Panis R, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000; 68:556-567.
12. Bruno R, Sacchi P, Scagnolari C, et al. Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naive patients with chronic hepatitis C: a randomized, controlled study. Aliment Pharmacol Ther 2007; 26:369-376.
13. Silva M, Poo J, Wagner F, et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol 2006; 45:204-213.
14. Di Bisceglie A, Ghalib R, Hamzeh F, Rustgi V. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat 2007; 14:721-729.
15. Dixit N, Layden-Almer J, Layden T, Perelson A. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004; 432: 922-924.
16. Torriani F, Ribeiro R, Gilbert T, et al. HCV and HIV dynamics during HCV treatment in HCV/HIV coinfection. J Infect Dis 2003; 188: 1498-1507.
17. Soriano V, Barreiro P, Martin-Carbonero L, et al. Update on the treatment of chronic hepatitis C in HIV-infected patients. AIDS Rev 2007; 9:99-113.
18. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21:1073-1089.
19. de Lédinghen V, Douvin C, Kettaneh A, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006; 41:175-179.
20. Larrat S, Stanke-Labesque F, Plages A, Zarski J, Bessard G, Souvignet C. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother 2003; 47:124-129.
21. Morello J, Rodriguez-Novoa S, Gonzalez-Pardo G, Jimenez-Nacher I, Soriano V. Measurement of plasma ribavirin concentrations using high-performance liquid chromatography after solid pnase extraction in patients treated for chronic hepatitis C. J Chromatogr B 2007; 29:802-806.
22. Crespo M, Sauleda S, Esteban J, et al. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. J Viral Hepat 2007; 14:228-238.
23. Ramos B, Nunez M, Rendon A, et al. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients. J Viral Hepat 2007; 14:387-391.
24. Jansen P, Reesink H. Antiviral effect of peginterferon alfa-2b and alfa-2a compared. J Hepatol 2006; 45:172-173.
25. Bruno R, Sacchi P, Ciappina V, et al. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: a randomized, controlled study. Antiviral Ther 2004; 9:491-497.
26. Formann E, Jessner W, Bennett L, Ferenci P. Twice-weekly administration of peginterferon-α-2b improves viral kinetics in patients with chronic hepatitis C virus genotype 1. J Viral Hepat 2003; 10:271-276.